Ken Coffey Presents AtriAN Medical at LSI USA ‘23

Transcription

Ken Coffey  0:05  

So I'm Ken Coffey with AtriAN so that if you listen to nothing, there's gonna be a slide right at the end to show some recent results we have. But basically, how many people in here know somebody that has AFib or has AFib themselves lots of people, it's a real problem. And the problem is that there really isn't a good solution for it. So we're taking a completely different radical approach to going at the source of it. What like I said, We're based in Ireland, we treated 36 patients, and we're using pulsed field ablation. That's sort of the New Energy. And in electrophysiology, most people are applying in a different way, we've raised about 6 million to date, and we're seeking about 29 million to get us through minimally invasive tools, the problem is really needs to be caught early, if you have afib. Early, if it different progresses, it kind of gets to where you just really can't do much about it. And there's companies that sort of focus on early stage, also late stage like Nature Cure, and we're trying to nip it in the bud right in the early, early stage of it. And the real complication is primarily stroke, you have basically the heart's not beating like it, should you develop these blood clots, and they go to the brain, these devastating strokes. So that's, that's what we're, we're trying to do, and there really isn't a good, there isn't really a good solution for it. So if you go to the ER, tonight, they're gonna give you drugs, and that's gonna make you sick and feel like crap. And then about 70% failure there, eventually, the electrophysiologist all sort of recommended ablation. And this is the key here is that in one year, 30% of those people are gonna have to have another ablation, and then three years 50% of those are gonna have to have a repeat ablation. So there's really no good way of doing that what they're doing is they're taking actually, this sort of this sort of this structural ablation, where they're burning, or they're freezing the inside of the heart around the pulmonary veins, in attempt to sort of block the signals that are coming in, we're going for the signals that exist outside the heart. So it's a huge market, everyone knows this. It's not even just a growing market, it's growing. Because we know more about it, my Apple Watch will tell me if I have afib. So that's there's a lot more awareness in the market than just in general. We're going to take it from open chest, I'll show you this pathway through minimally invasive. So what we're doing this is a little, little complex. So I'm gonna slow down here, the only patient population group that never gets a fib, well, maybe 5%, the only patient population that never gets a fib, our heart transplant patients, and you might think well, that's, of course have a new heart, right? No, even people who've received their own heart sort of auto transplantation study it was done some years ago. And because of these, you see up here, there's this connection between the the central nervous system and the autonomic system of the heart. If you disconnect those two, then the AFib goes away. And that's sort of what we're, we're that's that's not sort of we're doing that's what we're doing sort of sort of modulating bringing that that conductivity down a little bit, us we're going on the outside of the heart, which is, is not a common access, but we're going to make it so because we're treating those exact spots on the outside, we started with open chest, we have a pulse field generator, 1000 volts, very short duration, and basically ablates the nerves, but this is key, it doesn't harm the heart muscle. So all the ablation techniques right now, a burner freeze, and you're taking this healthy heart tissue and destroying it, we're not doing that. And you see here, Dr. skorulski, and Prague and hamaca, doing one of our treatments, that's our catheter, it's connected to a pulse field generator, and we're moving toward minimally invasive. So they're really in atrial fibrillation, there's sort of this multi team approach right now, if you'll see with a literature and their hybrid approach, they're using a electrophysiologist, cardiac surgeon. And that's where we're starting in the open chest because we can actually visualize these sites going after them. And that's what we've done in these 36 patients. But then we're going to use subxiphoid access, and then actually just go loop around and navigate sort of a minimally invasive approach eventually. So you see on the top there, this minimally invasive approach can take a little bit longer because we've already treated 36 patients in the open chest as you see below. So we should have CE marking in 2026. That should build the data also for the minimally invasive, little bit more design work to do there. We should be break even pretty soon, actually. 2028. So you see the revenue model here is quite strong, moving from open chest to minimally invasive, so it's a great opportunity for investors. The milestones today we've done a lot of preclinical work, the actual technology came out of mayo clinic. We incubated it in Ira And we did preclinical work, both at Mayo and to Ireland, other centers in, in, in Europe. And we've taken it through 36 patients clinically, the first 12 are done for safety and effect, sorry, safety and feasibility. And we just treated 12 patients that for efficacy, and I'll share that data with you now. I guess one more thing. So we've got a great IP portfolio. And it looks like I might, maybe, whoops, can I go back? Because all right, so I had the data slide there, it's late breaking news. Can't get it back. That's okay. So 12 patients we treated for efficacy, and at six month timeline, all are free from afib. So that was something we did not expect. We were hoping for maybe 40 or 50%. Our great team recent additions, John Hunt, chair, Mark Carlson, who's with CMO of avid St. Jude. So anyway, if you're interested in this approach, I'll be around the conference. Thanks very much. Thank you